{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:25:28Z","timestamp":1721348728876},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,18]]},"DOI":"10.7759\/cureus.64797","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T09:25:38Z","timestamp":1721294738000},"source":"Crossref","is-referenced-by-count":0,"title":["A Rare Presentation of Malignant Melanoma of the Face: A Case Report"],"prefix":"10.7759","author":[{"given":"Apurva","family":"Palatkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yash V","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manu","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur","family":"Ingale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Benign and malignant conditions of the skin","author":"Khan M","year":"2018","unstructured":"Khan M, Martin-Clavijo A. Benign and malignant conditions of the skin. Scott-Brown's Otorhinolaryngology and Head and Neck Surgery, 8th Edition. Watkinson J, Clarke R (ed): Taylor and Francis Group, Boca Raton (FL); 2018. 3:1321-36."},{"key":"ref2","article-title":"Malignant Melanoma","author":"Heistein JB","year":"2020","unstructured":"Heistein JB, Acharya U, Mukkamalla SK. Malignant Melanoma. StatPearls Publishing, Treasure Island( FL); 2020."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmir.2019.05.001","article-title":"The pathogenesis and clinical management of cutaneous melanoma: an evidence-based review","volume":"50","author":"Burns D","year":"2019","unstructured":"Burns D, George J, Aucoin D, Bower J, Burrell S, Gilbert R, Bower N. The pathogenesis and clinical management of cutaneous melanoma: an evidence-based review. J Med Imaging Radiat Sci. 2019, 50:460-469.e1. 10.1016\/j.jmir.2019.05.001","journal-title":"J Med Imaging Radiat Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4287","article-title":"Cutaneous melanoma: From pathogenesis to therapy (review)","volume":"52","author":"Leonardi GC","year":"2018","unstructured":"Leonardi GC, Falzone L, Salemi R, et al.. Cutaneous melanoma: From pathogenesis to therapy (review). Int J Oncol. 2018, 52:1071-80. 10.3892\/ijo.2018.4287","journal-title":"Int J Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.405","article-title":"Sex-related location of head and neck melanoma strongly argues for a major role of sun exposure in cars and photoprotection by hair","volume":"133","author":"Lesage C","year":"2013","unstructured":"Lesage C, Barbe C, Le Clainche A, Lesage FX, Bernard P, Grange F. Sex-related location of head and neck melanoma strongly argues for a major role of sun exposure in cars and photoprotection by hair. J Invest Dermatol. 2013, 133:1205-11. 10.1038\/jid.2012.405","journal-title":"J Invest Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1349","article-title":"Cutaneous malignant melanoma: a review of early diagnosis and management","volume":"12","author":"Naik PP","year":"2021","unstructured":"Naik PP. Cutaneous malignant melanoma: a review of early diagnosis and management. World J Oncol. 2021, 12:7-19. 10.14740\/wjon1349","journal-title":"World J Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4065\/82.3.364","article-title":"Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis","volume":"82","author":"Markovic SN","year":"2007","unstructured":"Markovic SN, Erickson LA, Rao RD, et al.. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007, 82:364-80. 10.4065\/82.3.364","journal-title":"Mayo Clin Proc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-020-01735-z","article-title":"Diagnosis of cutaneous melanoma: the gap between the knowledge of general practitioners and dermatologists in a Brazilian population","volume":"35","author":"Garrido AQ","year":"2020","unstructured":"Garrido AQ, Wainstein AJ, Brand\u00e3o MP, de Vasconcellos Santos FA, Bittencourt FV, Ledsham C, Drummond-Lage AP. Diagnosis of cutaneous melanoma: the gap between the knowledge of general practitioners and dermatologists in a Brazilian population. J Cancer Educ. 2020, 35:819-25. 10.1007\/s13187-020-01735-z","journal-title":"J Cancer Educ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.04.031","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"65","author":"Bichakjian CK","year":"2011","unstructured":"Bichakjian CK, Halpern AC, Johnson TM, et al.. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2011, 65:1032-47. 10.1016\/j.jaad.2011.04.031","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/196493","article-title":"Accuracy of diagnostic biopsy for cutaneous melanoma: implications for surgical oncologists","volume":"2013","author":"Hieken TJ","year":"2013","unstructured":"Hieken TJ, Hern\u00e1ndez-Irizarry R, Boll JM, Jones Coleman JE. Accuracy of diagnostic biopsy for cutaneous melanoma: implications for surgical oncologists. Int J Surg Oncol. 2013, 2013:196493. 10.1155\/2013\/196493","journal-title":"Int J Surg Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31829d7f35","article-title":"Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR)","volume":"37","author":"Scolyer RA","year":"2013","unstructured":"Scolyer RA, Judge MJ, Evans A, et al.. Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Am J Surg Pathol. 2013, 37:1797-814. 10.1097\/PAS.0b013e31829d7f35","journal-title":"Am J Surg Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21962","article-title":"Evidence-based treatment of early-stage melanoma","volume":"104","author":"Ross MI","year":"2011","unstructured":"Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol. 2011, 104:341-53. 10.1002\/jso.21962","journal-title":"J Surg Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3586","article-title":"Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells","volume":"49","author":"Akiyama Y","year":"2016","unstructured":"Akiyama Y, Nonomura C, Kondou R, et al.. Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. Int J Oncol. 2016, 49:1099-107. 10.3892\/ijo.2016.3586","journal-title":"Int J Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt027","article-title":"Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival","volume":"24","author":"Delyon J","year":"2013","unstructured":"Delyon J, Mateus C, Lefeuvre D, et al.. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013, 24:1697-703. 10.1093\/annonc\/mdt027","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi FS","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, et al.. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363:711-23. 10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur GA","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, et al.. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014, 15:323-32. 10.1016\/S1470-2045(14)70012-9","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long GV","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, et al.. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015, 386:444-51. 10.1016\/S0140-6736(15)60898-4","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma","volume":"86","author":"Hamid O","year":"2017","unstructured":"Hamid O, Puzanov I, Dummer R, et al.. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017, 86:37-45. 10.1016\/j.ejca.2017.07.022","journal-title":"Eur J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas A","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, et al.. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015, 16:908-18. 10.1016\/S1470-2045(15)00083-2","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.","volume":"16","author":"Weber JS","year":"2015","unstructured":"Weber JS, D'Angelo SP, Minor D, et al.. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.. Lancet Oncol. 2015, 16:375-84. 10.1016\/S1470-2045(15)70076-8","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/263983-a-rare-presentation-of-malignant-melanoma-of-the-face-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T09:25:41Z","timestamp":1721294741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/263983-a-rare-presentation-of-malignant-melanoma-of-the-face-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.64797","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,18]]}}}